Method for measuring concentration of biogenic amines in sample

The method and device using MRGPRX2 signals address the limitations of existing biogenic amine measurement methods by estimating histamine concentration, offering a cost-effective and efficient safety assessment in food and other products.

WO2026235528A1PCT designated stage Publication Date: 2026-11-12UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096755
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods for measuring biogenic amine concentrations in food products are costly, time-consuming, and do not account for the actual physiological impact on the human body, lacking the ability to verify the concentration's effect on health symptoms.

Method used

A method and device utilizing MRGPRX2 (MAS related GPR family member X2) signals, such as mRNA expression levels, protein levels, and mast cell degranulation indicators, to estimate histamine concentration in samples, correlating these signals with histamine levels through regression equations.

Benefits of technology

Provides a cost-effective and efficient means to assess biogenic amine safety by estimating histamine concentration, enabling quality control and safety evaluation in food, household goods, and pharmaceuticals, considering the actual physiological impact.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096755_12112026_PF_FP_ABST
    Figure KR2026096755_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a method for estimating the concentration of biogenic amines in a sample, comprising: treating mast cells with a sample, and then measuring a MRGPRX2-related signal induced in the mast cells; and estimating the concentration of histamine in the sample on the basis of the correlation between the MRGPRX2-related signal and the concentration of histamine among biogenic amines. According to the present invention, histamine concentration can be estimated using a relative expression level of MRGPRX2 mRNA, and one or more from among an MRGPRX2 protein level, a relative expression level of TPSAB1 mRNA, and a β-hexosaminidase release level, and by comparing the estimated histamine concentration with a predetermined reference value, the present invention can be effectively used in the fields of quality control and safety evaluation of food, household goods, pharmaceuticals, or compositions containing or likely to contain biogenic amines.
Need to check novelty before this filing date? Find Prior Art

Description

Method for measuring biogenic amine concentration in a sample

[0001] The present invention relates to a method for measuring the concentration of biogenic amines in a sample.

[0002]

[0003] Biogenic amines (BAs) that can be generated in fermented foods are low-molecular-weight nitrogen compounds naturally produced through the decarboxylation of amino acids or the amination and transamination reactions of amino groups in amine precursors. However, regarding the health effects of these BAs, clinical symptoms are perceived differently depending on individual sensitivity, and they are not recognized as diseases. Representative BAs include histamine, tyramine, putrescine, and cadaverine; they are generated during the processing of protein-rich fermented foods, which primarily include sausages, ham, cheese, soy sauce, and fermented fish products (such as salted seafood). Histamine poisoning may occur, and symptoms such as gastric and intestinal cramps—caused by excessive contraction of gastrointestinal muscles—may appear, including abdominal pain, vomiting, and diarrhea. Additionally, it can cause coughing by contracting bronchial muscles. If these effects occur chronically, they can cause diarrhea, loose stools, and a persistent dry cough, and may induce asthma; they can contract the uterus to cause menstrual pain; contract the heart muscle to cause symptoms of anxiety and palpitations; and they may be the cause of diseases such as insomnia, vascular headaches, esophageal reflux, gastritis, and gastric ulcers. Examples include tyramine, which can cause hypertension and neurotoxicity, and phenylethylamine, which can cause digestive and nervous system symptoms such as digestive disorders and anxiety and palpitations as general symptoms.

[0004] For this reason, some countries apply the BA's food content standards, and the Codex Alimentarius Commission establishes standards for histamine content. Regarding the legal toxicity standards for fish and fermented fish products in each country, the limit is set at 50 mg / kg in the United States, and 200-400 mg / kg in Australia, New Zealand, and Korea. The standard dosage adopted by the European Organization is set at 100 mg / kg for fresh fish with a maximum allowable limit of 200 mg / kg, 200-400 mg / kg for fermented and aged fish products, and 400 mg / kg for salted seafood products. For phenylethylamine, the standard is set at 30 mg / kg for general foods, and for tyramine, at 100-800 mg / kg.

[0005] Endocrine disruptors are defined as exogenous compounds that interfere with any process of hormones within the body, such as synthesis, secretion, transport, metabolism, binding, action, or elimination. The American Endocrine Society defines them as exogenous chemical substances or mixtures of chemical substances that can interfere with the action of hormones. Research into the health risks posed by endocrine disruptors began in earnest in the mid-20th century. Studies on the risks of bisphenol A (BPA) and phthalates led to regulations such as the ban on phthalate use in toys and the ban on BPA use in baby bottles in Europe and Canada.

[0006] In the case of biogenic amines, since not all biogenic substances are subject to regulation, histamine is primarily tested. The most intuitive method used is the HPLC measurement method to quantify histamine contained in food products, or a method using enzymes that produce histamine or peptides that readily bind to them.

[0007] In the case of environmental hazardous substances, methods for quantification using HPLC, similar to biogenic amines, or measurement methods using fluorescent magnetic particles have been developed.

[0008] The disadvantages of existing technologies lie in their reliance on simple concentration-dependent quantitative methods, the inability to verify the actual impact of concentration on physiological changes in the human body, and the high measurement costs and long measurement times. Representative examples include the HPLC method, which offers the advantages of high sensitivity and the ability to perform both quantitative and qualitative analysis; however, it has drawbacks such as the need for expensive equipment, large sample volumes for extraction and pretreatment, and a long time required for the entire process from pretreatment to analysis. Therefore, it is necessary to determine the concentration based on the actual activity that may occur within the body.

[0009] Accordingly, the inventors confirmed the binding of MRGPRX2 (MAS related GPR family member X2) with biogenic amines and endocrine disruptors through 3D structural analysis and binding energy analysis, and analyzed the MRGPRX2 mRNA expression and mast cell degranulation levels when biogenic amines were treated to mast cells, the correlation between MRGPRX2 expression levels, histamine concentration, and mast cell degranulation, the MRGPRX2 expression and degranulation levels in mast cells following histamine treatment, and the degranulation levels in mast cells following fermented food sample treatment. By confirming that the concentration of biogenic amines, particularly histamine concentration, can be analyzed through the MRGPRX2 mRNA expression and degranulation levels in mast cells, the inventors completed the present invention.

[0010]

[0011] The object of the present invention is to provide a method for estimating the concentration of a biogenic amine in a sample, a method for evaluating safety related to a biogenic amine in a sample, or a method for estimating the concentration of histamine for evaluating safety related to a biogenic amine in a sample.

[0012] Another objective of the present invention is to provide a device for estimating the concentration of a biogenic amine in a sample, a device for evaluating safety related to a biogenic amine in a sample, or a device for estimating the concentration of a histamine for evaluating safety related to a biogenic amine in a sample.

[0013]

[0014] To achieve the above objective, the present invention provides a method for evaluating the safety of biogenic amines in a sample, comprising: 1) treating mast cells with a sample; 2) measuring an MRGPRX2 (MAS related GPR family member X2) related signal in the mast cells treated with the sample; and 3) estimating the histamine concentration in the sample using the measured MRGPRX2 related signal.

[0015] The above method may further include a step of evaluating the biogenic amine-related safety of the sample by comparing the estimated histamine concentration with a preset reference value.

[0016] The above MRGPRX2-related signal may be one or more selected from the group consisting of MRGPRX2 mRNA expression level, MRGPRX2 protein level, and mast cell response indicators associated with MRGPRX2 activation, and the mast cell response indicators associated with MRGPRX2 activation may be TPSAB1 mRNA expression level or β-hexosaminidase release level.

[0017] If the above MRGPRX2 related signal is the MRGPRX2 mRNA expression level, step 3) above may involve estimating the histamine concentration through a linear prediction equation represented by Equation 16.

[0018] If the above MRGPRX2-related signal is at the MRGPRX2 protein level, step 3) above may involve estimating the histamine concentration through a linear prediction equation represented by Equation 17.

[0019] If the above MRGPRX2-related signal is the TPSAB1 mRNA expression level, step 3) above may involve estimating the histamine concentration through a linear prediction equation represented by Equation 18.

[0020] The above sample may be a food, household product, pharmaceutical, or a composition containing or potentially containing a biogenic amine.

[0021] The above-mentioned mast cells may be human-derived mast cells.

[0022] In addition, the present invention may provide an apparatus for evaluating the safety of biogenic amines in a sample, comprising: 1) a processing unit for bringing a sample into contact with mast cells; 2) a measurement unit for measuring an MRGPRX2 (MAS related GPR family member X2) related signal in mast cells treated with the sample; and 3) a calculation unit for calculating the histamine concentration in the sample using the measured MRGPRX2 related signal.

[0023] The above device may further include an evaluation unit that evaluates the biogenic amine-related safety of the sample by comparing the calculated histamine concentration with a preset reference value.

[0024]

[0025] The present invention relates to a method for estimating the concentration of biogenic amines in a sample, wherein a sample is treated to mast cells and an MRGPRX2-related signal induced in the mast cells is measured, and the concentration of histamine in the sample can be estimated based on the correlation between the MRGPRX2-related signal and the concentration of histamine among biogenic amines.

[0026] According to the present invention, the histamine concentration can be estimated using one or more of the MRGPRX2 mRNA relative expression level, as well as the MRGPRX2 protein level, the TPSAB1 mRNA relative expression level, and the β-hexosaminidase release level, and by comparing the estimated histamine concentration with a preset reference value, it can be usefully utilized in the field of quality control and safety evaluation of food, household goods, pharmaceuticals, or compositions containing or potentially containing biogenic amines.

[0027]

[0028] FIG. 1 is a diagram showing the 3D structure of MRGPRX2 (MAS related GPR family member X2). In the diagram, TM1 to TM7 represent the first to seventh membrane penetration regions, respectively.

[0029] Figure 2 is a figure showing the binding structure of biogenic amines and MRGPRX2.

[0030] Figure 3 is a figure showing the binding structure of endocrine disruptors and MRGPRX2.

[0031] Figure 4 shows the expression levels of MRGPRX2 mRNA and mast cell degranulation levels following treatment with biogenic amines. In the figure, C48 represents Compound 48 / 80, Cad represents cadaverine, Tyr represents tyramine, Tryp represents tryptamine, 3-MCPD represents 3-monochloropropane-1,2-diol, and His represents histamine.

[0032] Figure 5 shows the levels of MRGPRX2 mRNA expression and mast cell degranulation in mast cells according to histamine concentration.

[0033] Figure 6 is a figure showing the correlation between the expression level of MRGPRX2, histamine concentration, and mast cell degranulation level.

[0034] Figure 7 shows the MRGPRX2 mRNA expression levels in mast cells and the histamine content in commercially fermented soy sauce and shrimp paste samples according to treatment with commercially available fermented soy sauce and shrimp paste samples. In the figure, C48 / 80 refers to compound 48 / 80, and DS, FS, JS, and FSS represent the experimental groups, respectively.

[0035] Figure 8 shows the level of degranulation of mast cells according to treatment with commercially available fermented soy sauce and salted shrimp samples. In the figure, C48 / 80 refers to compound 48 / 80, and DS, FS, JS, and FSS represent the experimental groups, respectively.

[0036] Figure 9 shows the levels of MRGPRX2 mRNA expression, MRGPRX2 protein, TPSAB1 mRNA expression, and β-hexosaminidase release in mast cells according to histamine concentration. In the figure, CON represents the untreated control group, COM represents the positive control group treated with compound 48 / 80, and ND represents no detection.

[0037] Figure 10 is a figure showing the correlation between MRGPRX2 mRNA expression level, MRGPRX2 protein level, TPSAB1 mRNA expression level, histamine concentration, and β-hexosaminidase release level.

[0038] Figure 11 shows the levels of MRGPRX2 mRNA expression and β-hexosaminidase release in mast cells following treatment with fermented food samples. In the figure, CON represents the untreated control group, COM represents the positive control group treated with compound 48 / 80, and DS, FS, JS, and FSS represent the experimental groups, respectively.

[0039]

[0040] The terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Therefore, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, unless specifically stated otherwise, this means that it does not exclude other components but may include additional components.

[0041] Throughout this specification, '%' used to indicate the concentration of a particular substance is (w / w) % for solid / solid, (w / v) % for solid / liquid, and (v / v) % for liquid / liquid, unless otherwise noted.

[0042] The present invention provides a method for evaluating the safety of biogenic amines in a sample, comprising: 1) treating mast cells with a sample; 2) measuring an MRGPRX2 (MAS related GPR family member X2) related signal in the mast cells treated with the sample; and 3) estimating the histamine concentration in the sample using the measured MRGPRX2 related signal.

[0043] The above method may be, but is not limited to, a method for estimating the concentration of a biogenic amine in a sample, a method for estimating the concentration of histamine in a sample, or a method for estimating the concentration of histamine for safety assessment related to a biogenic amine in a sample.

[0044] In one embodiment of the present invention, step 3) may be a step of estimating the histamine concentration in a sample based on a pre-established correlation model between the measured MRGPRX2-related signal and the histamine concentration. The pre-established correlation model may be a linear regression model, a non-linear regression model, a multiple regression model, a weighted average model, an ensemble model, or a combination thereof, but is not limited thereto.

[0045] In one embodiment of the present invention, the correlation model may include at least one of mathematical formulas 1 to 14, or a combination thereof, but is not limited thereto.

[0046] The above method may further include, but is not limited to, a step of evaluating the biogenic amine-related safety of the sample by comparing the estimated histamine concentration with a preset reference value.

[0047] The above-mentioned preset reference value may be, but is not limited to, an acceptable histamine reference value, a control reference value, a quality control reference value, a regulatory reference value, or an experimentally set reference value established for food, household goods, pharmaceuticals, or compositions containing or potentially containing biogenic amines. For example, if the sample is food, the reference value may be an acceptable histamine reference value in food.

[0048] The above MRGPRX2-related signals may include MRGPRX2 mRNA expression levels, MRGPRX2 protein levels, and mast cell response indicators associated with MRGPRX2 activation, and the mast cell response indicators associated with MRGPRX2 activation may be TPSAB1 mRNA expression levels or β-hexosaminidase release levels, but are not limited thereto.

[0049] Meanwhile, although TPSAB1 mRNA expression levels do not represent the expression levels of MRGPRX2 itself, they serve as indicators related to mast cell activation and degranulation reactions following histamine treatment and can correlate with MRGPRX2 mRNA expression levels, MRGPRX2 protein levels, histamine concentration, and β-hexosaminidase release levels. Therefore, TPSAB1 mRNA expression levels can be utilized as auxiliary or transit indicators in MRGPRX2-based histamine concentration estimation models.

[0050] If the above MRGPRX2-related signal is the MRGPRX2 mRNA expression level, step 3) above may estimate the histamine concentration through a linear prediction equation represented by the following mathematical formula 16, but is not limited thereto.

[0051] [Mathematical Formula 16]

[0052] Y = aX + b

[0053] Here, Y is the histamine concentration (μg / mL) and X is the relative expression level of MRGPRX2 mRNA, and the above linear prediction equation may have a coefficient of determination (R²) between the relative expression level of MRGPRX2 mRNA and the histamine concentration of 0.9630 or higher.

[0054] The above a and b may be pairs of coefficients calculated together by regression analysis on a calibration dataset between MRGPRX2 mRNA relative expression levels and histamine concentrations, wherein a may be 27 to 42 and b may be 72 to 170. Preferably, a and b may be any one selected from pairs of coefficients consisting of 30.43 and 74.64, 27.71 and 168.3, 41.68 and 115.93, 28.72 and 155.32, and 32.71 and 146.48, but are not limited thereto.

[0055] When the coefficient pairs of a and b are 30.43 and 74.64, respectively, Equation 16 can be expressed as Equation 1 below, and Equation 1 below may be an equation for directly estimating histamine concentration from the relative expression amount of MRGPRX2 mRNA.

[0056] [Mathematical Formula 1]

[0057] Y = 30.43X + 74.64

[0058] Here, Y is the histamine concentration (μg / mL) and X is the relative expression level of MRGPRX2 mRNA.

[0059] When the coefficient pairs of a and b are 27.71 and 168.3, respectively, Equation 16 can be expressed as Equation 6 below, and Equation 6 below may be an equation for directly estimating histamine concentration from the relative expression amount of MRGPRX2 mRNA.

[0060] [Mathematical Formula 6]

[0061] Y = 27.71X + 168.3

[0062] Here, Y is the histamine concentration (μg / mL) and X is the relative expression level of MRGPRX2 mRNA.

[0063] When the coefficient pairs of a and b are 41.68 and 115.93, respectively, Equation 16 can be expressed as Equation 12 below, and Equation 12 below may be an equation derived based on a pathway of estimating the MRGPRX2 protein level from the relative expression amount of MRGPRX2 mRNA and then estimating the histamine concentration from the MRGPRX2 protein level.

[0064] [Mathematical Formula 12]

[0065] Y = 41.68X + 115.93

[0066] Here, Y is the histamine concentration (μg / mL) and X is the relative expression level of MRGPRX2 mRNA.

[0067] When the coefficient pairs of a and b are 28.72 and 155.32, respectively, Equation 16 can be expressed as Equation 13 below, and Equation 13 below may be an equation derived based on a pathway of estimating the relative expression of TPSAB1 mRNA from the relative expression of MRGPRX2 mRNA, and then estimating the histamine concentration from the relative expression of TPSAB1 mRNA.

[0068] [Mathematical Formula 13]

[0069] Y = 28.72X + 155.32

[0070] Here, Y is the histamine concentration (μg / mL) and X is the relative expression level of MRGPRX2 mRNA.

[0071] When the coefficient pairs of a and b are 32.71 and 146.48, respectively, Equation 16 may be expressed as Equation 14 below, and Equation 14 below may be an ensemble prediction formula derived by integrating two or more prediction values ​​among the predicted histamine concentration value calculated directly from the relative expression level of MRGPRX2 mRNA, the predicted histamine concentration value calculated via the MRGPRX2 protein level, and the predicted histamine concentration value calculated via the relative expression level of TPSAB1 mRNA. Specifically, the ensemble prediction formula may be derived by assigning weights based on the coefficient of determination (R²), correlation coefficient, prediction error, or a combination thereof for each prediction pathway, and applying said weights to the predicted histamine concentration value of each pathway, but is not limited thereto.

[0072] [Mathematical Formula 14]

[0073] Y = 32.71X + 146.48

[0074] Here, Y is the histamine concentration (μg / mL) and X is the relative expression level of MRGPRX2 mRNA.

[0075] In this specification, MRGPRX2 mRNA relative expression levels and TPSAB1 mRNA relative expression levels refer to relative expression levels compared to the control group, unless otherwise specified.

[0076] If the above MRGPRX2-related signal is at the MRGPRX2 protein level, step 3) above may estimate the histamine concentration through a linear prediction equation represented by the following mathematical formula 17, but is not limited thereto.

[0077] [Mathematical Formula 17]

[0078] Y = cX + d

[0079] Here, Y is histamine concentration (μg / mL) and X is MRGPRX2 protein level (ng / mL), and the linear prediction equation may have a coefficient of determination (R²) between the MRGPRX2 protein level and histamine concentration of 0.9910 or higher.

[0080] The above c and d may be a pair of coefficients calculated together by regression analysis on a calibration dataset between MRGPRX2 protein levels and histamine concentrations, wherein c is 46 to 48 and d is 132 to 136. Preferably, c and d may be a pair of coefficients of 46.79 and 134.2, respectively, but are not limited thereto.

[0081] When the coefficient pairs of c and d are 46.79 and 134.2, respectively, Equation 17 can be expressed as Equation 3 below.

[0082] [Mathematical Formula 3]

[0083] Y = 46.79X + 134.2

[0084] Here, Y is the histamine concentration (μg / mL) and X is the MRGPRX2 protein level (ng / mL).

[0085] If the above MRGPRX2-related signal is the TPSAB1 mRNA expression level, step 3) above may estimate the histamine concentration through a linear prediction equation represented by the following mathematical formula 18, but is not limited thereto.

[0086] [Mathematical Formula 18]

[0087] Y = eX + f

[0088] Here, Y is histamine concentration (μg / mL) and X is the relative expression level of TPSAB1 mRNA, and the above linear prediction equation may have a coefficient of determination (R²) of 0.9859 or higher between the relative expression level of TPSAB1 mRNA and the histamine concentration.

[0089] The above e and f may be a pair of coefficients calculated together by regression analysis on a calibration dataset between TPSAB1 mRNA relative expression levels and histamine concentrations, wherein e is 24 to 26 and f is 154 to 158. Preferably, e and f may be a pair of coefficients of 25.04 and 156.4, respectively, but are not limited thereto.

[0090] When the coefficient pairs of e and f are 25.04 and 156.4, respectively, Equation 18 can be expressed as Equation 9 below.

[0091] [Mathematical Formula 9]

[0092] Y = 25.04X + 156.4

[0093] Here, Y is the histamine concentration (μg / mL) and X is the relative expression level of TPSAB1 mRNA.

[0094] The above mathematical formulas may be calibration formulas or prediction formulas of one embodiment derived based on a specific cell line, treatment time, analysis method, and calibration dataset, and the histamine concentration estimation method of the present invention is not limited to the above mathematical formulas or the above numerical ranges. Those skilled in the art may establish and use separate calibration formulas or correlation models depending on the type of sample, the type of mast cell, culture conditions, treatment time, measurement method, or analysis conditions.

[0095] In one embodiment of the present invention, the method may further include a step of cross-checking the reliability of the estimated histamine concentration. The cross-checking step may be performed by comparing the β-hexosaminidase release level predicted from the estimated histamine concentration with the β-hexosaminidase release level predicted from the MRGPRX2 mRNA expression level. The more similar the predicted values ​​of the β-hexosaminidase release levels calculated from the two pathways are to each other, the more the estimated histamine concentration can be determined to be consistent with the degranulation reaction of mast cells.

[0096] The above sample may be a food, household product, pharmaceutical, or a composition containing or potentially containing a biogenic amine, but is not limited thereto. The above food may be a fermented food, and the fermented food may be a soy sauce, soy sauce, soybean paste, red pepper paste, cheese, ham, sausage, fermented fish product, salted seafood product, fermented crustacean product, or a combination thereof, but is not limited thereto.

[0097] The mast cells may be human-derived mast cells, preferably HMC-1.2 cells, but are not limited thereto. For example, the mast cells may be cells that express MRGPRX2 or may exhibit a degranulation reaction, changes in TPSAB1 mRNA expression, changes in β-hexosaminidase release, or a combination thereof upon MRGPRX2 activation.

[0098] The MRGPRX2 mRNA expression levels and TPSAB1 mRNA expression levels can be measured by qRT-PCR, RT-PCR, digital PCR, nucleic acid amplification, hybridization assay, or a combination thereof. The MRGPRX2 protein level can be measured by ELISA, Western blot, immunoassay, fluorescence immunoassay, or a combination thereof. The β-hexosaminidase release level can be measured by a β-hexosaminidase assay, enzyme activity assay, absorbance assay, or a combination thereof.

[0099] In addition, the present invention provides an apparatus for evaluating the safety of biogenic amines in a sample, comprising: 1) a processing unit for contacting a sample with mast cells; 2) a measurement unit for measuring an MRGPRX2 (MAS related GPR family member X2) related signal in mast cells treated with the sample; and 3) a calculation unit for calculating a histamine concentration in the sample using the measured MRGPRX2 related signal.

[0100] The above device may be a device for estimating the concentration of a biogenic amine in a sample, a device for estimating the concentration of a histamine in a sample, or a device for estimating the concentration of a histamine for safety assessment related to a biogenic amine in a sample, but is not limited thereto.

[0101] The device may further include a storage unit that stores a pre-established correlation model between the measured MRGPRX2-related signal and the histamine concentration. The storage unit may store a regression equation, coefficients, coefficient of determination (R²), weights, reference values, or a combination thereof between the MRGPRX2-related signal and the histamine concentration.

[0102] The above device may further include, but is not limited to, an evaluation unit that evaluates the biogenic amine-related safety of the sample by comparing the estimated histamine concentration with a preset reference value.

[0103] The processing unit may include a reaction vessel, a culture unit, a well plate, a microplate, or a combination thereof for contacting a sample with mast cells. The measurement unit may include a qRT-PCR device, a nucleic acid amplification device, an ELISA reader, an absorbance meter, a fluorescence meter, an enzyme activity meter, or a combination thereof. The output and evaluation units may be implemented by a processor, a control unit, an arithmetic unit, a computer, software, or a combination thereof.

[0104] In one embodiment of the present invention, the device may further include a detection reagent unit for measuring an MRGPRX2-related signal, or be provided together with a detection kit including said detection reagent unit.

[0105] The above detection reagent part may include, but is not limited to, a primer or probe for measuring MRGPRX2 mRNA relative expression level, a primer or probe for measuring TPSAB1 mRNA relative expression level, an antibody for measuring MRGPRX2 protein level, a reagent for measuring β-hexosaminidase release level, a reagent for qRT-PCR, a reagent for nucleic acid extraction, a substrate for measuring enzyme activity, a standard histamine solution, a buffer, or a combination thereof.

[0106] Additionally, the detection reagent unit may further include, but is not limited to, a positive control, a negative control, a standard substance for calibration curve preparation, a cell culture medium, a solution for sample dilution, a reaction vessel, a well plate, a microplate, or a combination thereof.

[0107] The detection reagent unit may be used together with the processing unit, measurement unit, storage unit, output unit, or evaluation unit, and the MRGPRX2-related signal measured using the detection reagent unit may be used to calculate histamine concentration or evaluate the safety of a sample related to biogenic amines based on a correlation model, regression equation, coefficient, or reference value stored in the storage unit.

[0108] The above device may further include an instruction manual describing the method of use of the detection reagent unit, sample processing conditions, method of measuring MRGPRX2-related signals, method of calculating histamine concentration, method of applying a correlation model, or method of comparing reference values, or may be provided together with the instruction manual.

[0109]

[0110] The advantages and features of the present invention, and the methods for achieving them, will become clear by referring to the embodiments described in detail below. Hereinafter, the present invention will be described in detail by way of embodiments. However, these embodiments are intended to specifically explain the present invention, and the scope of the present invention is not limited to these embodiments.

[0111]

[0112] [Example 1] Analysis of binding affinity between biogenic amines and endocrine disruptors and MRGPRX2 (MAS-related GPR family member X2)

[0113] The chemical structures of biogenic amines and endocrine disruptors were analyzed using the PubChem database, and the 3D structure of MRGPRX2 was obtained from the RSCB PDB (Protein Data Base). After converting it to PDBQT format using AutodockTools (v1.5.7), the binding with MRGPRX2 (MAS related GPR family member X2) was confirmed using the molecular docking program AutoDock Vina (v 1.2.5). The analysis results were visualized using PyMOL (v 3.1.1).

[0114] Figure 1 shows the 3D structure of MRGPRX2 (MAS-related GPR family member X2), Figure 2 shows the binding structure between a biogenic amine and MRGPRX2, and Table 1 below shows the binding affinity between a biogenic amine and MRGPRX2. Looking at Figure 2, it was found that biogenic amines, excluding tyramine, bind to the same domain within MRGPRX2. Additionally, looking at Table 1, it was found that the binding affinity of all biogenic amines to MRGPRX2 was lower than -3. Since it is determined that the two substances bind starting from a binding affinity of -3, it can be confirmed that all biogenic amines bind to MRGPRX2.

[0115]

[0116]

[0117] In addition, Figure 3 shows the binding affinity of endocrine disruptors with MRGPRX2. Looking at Figure 3, it was found that all substances except DHEP and Glyphosate bind to the same domain of MRGPRX2 as the control, Estradiol (E2, Estrogen). Furthermore, looking at Table 1 above, it can be confirmed that all endocrine disruptors exhibit lower binding energies compared to biogenic amines, indicating that they possess stronger binding affinity compared to biogenic amines. In particular, DINP exhibited the lowest binding energy, indicating a strong binding affinity compared to the positive control.

[0118]

[0119] [Example 2] Analysis of MRGPRX2 Expression and Degranulation Levels in Mast Cells Following Biogenic Amine Treatment

[0120] Incubate for 24 hours to obtain 2 x 10 6Human mast cells prepared in a plate to a cell / ml concentration were treated with biogenic amines (Cadaverine 1 mM, Tyramine 0.5 mM, Tryptamine 0.05 mM, 3-MCPD 1 mM, Histamine 3.6 mM; concentrations that do not affect mast cell toxicity) for 24 hours. After harvesting the cells, RNA was isolated using QIAzol (QIAGEN, Germantown, MD, USA), MRGPRX2 primer (Bioneer, Daejeon, Korea) and RNA polymerase (SYBR green RT-PCR kit, Bioneer, Daejeon, Korea) were added, and mRNA expression levels were analyzed using a qRT-PCR instrument (Thermal Cycler Dice Real-Time System III, Takara Bio Inc, Shiga, Japan). Compound 48 / 80 was used as a positive control at a concentration of 10 μg / ml, and Histamine was used at 200 μg / ml (based on 200 mg / L-codex). For the degranulation of mast cells, mast cells treated with biogenic amines for 24 hours were collected, suspended in PBS, sonicated, and centrifuged to obtain a supernatant. The supernatant was then reacted using a β-Hexosaminidase assay kit (TRIBIOSCIENCE, Palo Alto, CA, USA), and the level of degranulation was analyzed using an absorbance analyzer (Tecan, Sunrise, Switzerland).

[0121] The analysis results are shown in Figure 4. As shown in Figure 4, when biogenic amines were applied to mast cells, the MRGPRX2 mRNA expression of the mast cells increased by at least 2 to more than 10 times compared to the control group, and the level of degranulation was found to increase significantly compared to the control group. Through these results, it was confirmed that biogenic amines have activity that promotes MRGPRX2 mRNA expression and degranulation in mast cells.

[0122]

[0123] [Example 3] Analysis of MRGPRX2 mRNA expression and degranulation levels in mast cells according to histamine concentration

[0124] Mast cells were treated with histamine at concentrations of 0, 100, 200, 400, and 800 μg / mL for 24 hours, and the cells were collected. RNA was isolated using QIAzol (QIAGEN, Germantown, MD, USA), and after adding MRGPRX2 primer (Bioneer, Daejeon, Korea) and RNA polymerase (SYBR green RT-PCR kit, Bioneer, Daejeon, Korea), mRNA expression levels were analyzed using a qRT-PCR instrument (Thermal Cycler Dice Real-Time System III, Takara Bio Inc, Shiga, Japan). For the degranulation of mast cells, mast cells treated with histamine at different concentrations for 24 hours were collected, suspended in PBS, sonicated, and centrifuged to obtain a supernatant. The supernatant was then reacted using a β-Hexosaminidase assay kit (TRIBIOSCIENCE, Palo Alto, CA, USA), and the level of degranulation was analyzed using an absorbance analyzer (Tecan, Sunrise, Switzerland).

[0125] Figure 5A shows the results of the analysis of MRGPRX2 expression according to histamine concentration. Looking at Figure 5A, when treated with 400 μg / mL of histamine, the MRGPRX2 expression level was 10 times higher than that of the control group, and when treated with 800 μg / mL of histamine, the MRGPRX2 expression level was 20 times higher than that of the control group.

[0126] In addition, Figure 5B shows the results of the analysis of the level of degranulation according to histamine concentration. Looking at Figure 5B, treatment with 400 μg / mL of histamine showed a 20% higher level of degranulation compared to the control group, and treatment with 800 μg / mL of histamine showed a 40% higher level of degranulation compared to the control group.

[0127] Through the above results, it was confirmed that the MRGPRX2 mRNA expression level and degranulation level increased in a concentration-dependent manner with respect to histamine.

[0128]

[0129] [Example 4] Analysis of the correlation between MRGPRX2 expression levels, histamine concentration, and mast cell degranulation

[0130] Correlation analysis between MRGPRX2 expression levels, histamine concentration, and mast cell degranulation was performed using Pearson correlation analysis and Spearman rank correlation analysis with the Prism program. In the Pearson analysis, significance was examined by calculating the r-value, 95% confidence interval, coefficient of determination (R²), and two-tailed p-value, and correlation was also confirmed in the Spearman analysis based on the r-value, 95% confidence interval, and p-value.

[0131] Figure 6A shows the results of the correlation analysis between MRGPRX2 expression levels and histamine concentration. Looking at Figure 6A, the value r is 0.9737 (p<0.0001), confirming that there is a significant correlation between MRGPRX2 expression levels and histamine concentration. Additionally, Figure 6B shows the correlation between MRGPRX2 expression levels and degranulation levels. Looking at Figure 6B, the value r is 0.9126 (p<0.001), confirming that there is a significant correlation between MRGPRX2 expression levels and degranulation levels.

[0132]

[0133] [Example 5] Analysis of changes in MRGPRX2 expression and degranulation in mast cells following histamine treatment

[0134] Commercially available fermented soy sauce (DS, FS, JS) and salted shrimp paste (FSS) were used as samples, and samples were prepared by diluting them to a salinity of 0.15%. In addition, human mast cells were cultured at 2 x 10 6 The concentration was prepared to be cells / ml, and 5 μL of each sample was added to plates cultured with mast cells and incubated for 24 hours. Compound 48 / 80 at 10 μg / ml and histamine at 200 μg / ml (200 mg / L - according to Codex) were used as positive controls. After the reaction was completed, cells were collected, RNA was isolated from each sample, and mRNA expression levels were confirmed by performing MRGPRX2 qRT-PCR.

[0135] Figure 7A shows the results of the MRGPRX2 mRNA expression analysis. Looking at Figure 7A, treatment with compound 48 / 80 showed a 7-fold increase in MRGPRX2 mRNA expression compared to the control group, and treatment with histamine showed a 10-fold increase in MRGPRX2 mRNA expression compared to the control group. Treatment with fermented soy sauce showed a level of MRGPRX2 mRNA expression similar to the control group, and treatment with salted shrimp showed a 17-fold increase in mRNA expression compared to the control group.

[0136] To confirm the relationship between the above results and the histamine content contained in the food, the histamine concentrations of the fermented soy sauce and salted shrimp samples were checked. The results of the concentration check are shown in Fig. 7B. Looking at Fig. 7B, all fermented soy sauce samples showed histamine content of 200 mg / L or less, which is the Codex standard, but the salted shrimp samples showed histamine content exceeding the Codex standard by more than three times.

[0137]

[0138] [Example 6] Analysis of the level of mast cell degranulation following treatment of fermented food samples

[0139] The level of degranulation of mast cells was analyzed following sample treatment with commercially available fermented soy sauce (DS, FS, JS) and salted shrimp paste (FSS). Mast cells treated with fermented soy sauce (DS, FS, JS) and salted shrimp paste (FSS) samples for 24 hours were collected, suspended in PBS, sonicated, and centrifuged to obtain a supernatant. The supernatant was then reacted using a β-Hexosaminidase assay kit (TRIBIOSCIENCE, Palo Alto, CA, USA) and analyzed using an absorbance analyzer (Tecan, Sunrise, Switzerland).

[0140] The analysis results are shown in Figure 8. Looking at Figure 8, when fermented soy sauce (DS, FS, JS) samples with histamine content lower than the Codex standard of 200 mg / L were treated, no significant change in the level of degranulation was observed compared to the control group; on the other hand, when salted shrimp samples with histamine content higher than the Codex standard of 200 mg / L were treated, a significantly higher level of degranulation was observed compared to the control group. Through these results, it was confirmed that the level of degranulation in mast cells increased in a concentration-dependent manner with respect to histamine in food, exhibiting a trend similar to that observed when the expression of MRGPRX2 increased in a concentration-dependent manner with respect to histamine.

[0141]

[0142] [Example 7] Analysis of Extended Correlation Between Histamine Concentration and Mast Cell Response Using Multiple Indicators

[0143] In Examples 3 and 4 above, the correlation between MRGPRX2 mRNA expression levels, histamine concentration, and mast cell degranulation levels was confirmed. In this example, the analysis was extended to include not only MRGPRX2 mRNA expression levels but also MRGPRX2 protein levels and TPSAB1 mRNA expression levels as additional indicators, and the correlation with histamine concentration and β-hexosaminidase release levels was analyzed.

[0144] Correlation analysis was performed to evaluate the correlations between MRGPRX2 and TPSAB1 gene expression, MRGPRX2 protein levels, histamine concentration, and β-hexosaminidase release levels. Pearson correlation, Spearman rank correlation, and linear regression analysis were performed using GraphPad Prism (version 8.0), and the correlation coefficient (r), 95% confidence interval (CI), and p-value were determined.

[0145] Specifically, the expression levels of MRGPRX2 mRNA and TPSAB1 mRNA were measured by performing qRT-PCR after isolating total RNA from HMC-1.2 cells, and relative expression levels were calculated using β-actin as an internal control. MRGPRX2 protein levels were measured using a human MRGPRX2 ELISA kit. β-hexosaminidase release levels were determined by measuring enzyme activity in the supernatant and cell lysates obtained after cell treatment, converting the enzyme activity in the supernatant into a ratio of total enzyme activity, and calculating the relative value compared to the control group.

[0146] Changes in MRGPRX2 mRNA expression, MRGPRX2 protein levels, TPSAB1 mRNA expression, and β-hexosaminidase release levels according to histamine concentration are shown in Figure 9. In addition, the results of the correlation analysis between each indicator are shown in Figure 10 and Table 2.

[0147] Looking at Table 2 below, high coefficient of determination (R²) between MRGPRX2 mRNA expression level and histamine concentration, MRGPRX2 protein concentration and histamine concentration, and TPSAB1 mRNA expression level and histamine concentration 2 ) and Pearson correlation coefficients were confirmed. In addition, MRGPRX2 mRNA expression level, MRGPRX2 protein concentration, TPSAB1 mRNA expression level, and histamine concentration showed a high correlation with β-hexosaminidase release level.

[0148] Mathematical Formula Number Independent Variable (X) Dependent Variable (Y) Regression Equation R 2Pearson r2MRGPRX2 mRNAMRGPRX2 protein (ng / mL)Y = 0.8909X - 0.39040.99040.99523MRGPRX2 proteinHistamine(μg / mL)Y = 46.79X + 134.20.99100.99554TPSAB1 mRNAMRGPRX2 proteinY = 0.8085X - 0.13850.99450.99735MRGPRX2 proteinβ-hex release (%)Y = 2.259X + 0.76940.95880.97926MRGPRX2 mRNAHistamine(μg / mL)Y = 27.71X + 168.30.98930.99467MRGPRX2 mRNATPSAB1 mRNAY = 1.147X - 0.043050.97680.99848MRGPRX2 mRNAβ-hex release (%)Y = 1.364X + 102.90.94000.96959TPSAB1 mRNAHistamineY = 25.04X + 156.40.98590.992910TPSAB1 mRNAβ-hex release (%)Y = 1.279X + 101.80.95650.978111Histamine(μg / mL)β-hex release (%)Y = 0.0404X + 95.120.95790.9787

[0149]

[0150] In particular, TPSAB1 mRNA expression levels in the histamine-treated groups at 400 μg / mL and 800 μg / mL were found to increase 11.6-fold and 26.3-fold, respectively, compared to the control group (Fig. 9). In addition, a high positive correlation was confirmed between MRGPRX2 mRNA expression levels and TPSAB1 mRNA expression levels, and TPSAB1 mRNA expression levels also showed a high correlation with histamine concentration and β-hexosaminidase release levels.

[0151] From the above results, it was confirmed that MRGPRX2 mRNA expression levels, MRGPRX2 protein concentrations, and TPSAB1 mRNA expression levels can be used as indicators to calculate histamine concentration in a sample, and that β-hexosaminidase release levels can be used as auxiliary indicators to cross-check the reliability of the calculated histamine concentration.

[0152]

[0153] [Example 8] Prediction of Multipath Histamine Concentration Based on MRGPRX2 Expression Level

[0154] Based on the regression equation between multiple indicators identified in Example 7 above, multiple pathways were established to predict histamine concentration from MRGPRX2 mRNA expression levels. The prediction pathways of this example were derived by combining each regression equation listed in Table 2 above, and are intended to calculate histamine concentration directly or indirectly from MRGPRX2 mRNA expression levels.

[0155] First, the first pathway is a pathway that directly predicts histamine concentration from MRGPRX2 mRNA expression levels, and can be predicted based on Equation 6 of Table 2 above.

[0156] [Mathematical Formula 6]

[0157] Y = 27.71X + 168.3

[0158] Here, Y is the histamine concentration, and X is the relative expression level of MRGPRX2 mRNA.

[0159] Next, the second pathway is a pathway that predicts the MRGPRX2 protein concentration from the MRGPRX2 mRNA expression level and then predicts the histamine concentration from the MRGPRX2 protein concentration, and was derived as the following Equation 12 based on Equations 2 and 3 of Table 2.

[0160] [Mathematical Formula 12]

[0161] Y = 41.68X + 115.93

[0162] (=46.79(0.8909X - 0.3904) + 134.2)

[0163] Here, Y is the histamine concentration, and X is the relative expression level of MRGPRX2 mRNA.

[0164] Next, the third pathway is a pathway that predicts the TPSAB1 mRNA expression level from the MRGPRX2 mRNA expression level and then predicts the histamine concentration from the TPSAB1 mRNA expression level, and was derived as the following Equation 13 based on Equations 7 and 9 of Table 2.

[0165] [Mathematical Formula 13]

[0166] Y = 28.72X + 155.32

[0167] (=25.04(1.147X - 0.04305) + 156.4)

[0168] Here, Y is the histamine concentration, and X is the relative expression level of MRGPRX2 mRNA.

[0169] From the above results, it was confirmed that MRGPRX2 mRNA expression levels can be utilized not only as an indicator for directly predicting histamine concentration, but also as a reference indicator for calculating histamine concentration through multiple prediction pathways via MRGPRX2 protein levels or TPSAB1 mRNA expression levels.

[0170]

[0171] [Example 9] Effective coefficient of determination and R²-weighted ensemble histamine concentration prediction model for multiple pathways

[0172] In order to integrate the multiple prediction paths set in Example 8 above, the effective coefficient of determination (R²) of each path was calculated, and a weighted ensemble analysis based on the effective coefficient of determination was performed.

[0173] As shown in Table 3 below, since the first pathway is a pathway that directly predicts histamine concentration from the MRGPRX2 mRNA expression level, the coefficient of determination of Equation 6 in Table 2, 0.9893, was used as the effective coefficient of determination for the first pathway. Since the second pathway is a pathway that predicts histamine concentration from the MRGPRX2 protein concentration after predicting the MRGPRX2 mRNA expression level, the effective coefficient of determination for the second pathway was calculated by multiplying the coefficient of determination of Equation 2 in Table 2 and the coefficient of determination of Equation 3. Since the third pathway is a pathway that predicts histamine concentration from the TPSAB1 mRNA expression level after predicting the MRGPRX2 mRNA expression level, the effective coefficient of determination for the third pathway was calculated by multiplying the coefficient of determination of Equation 7 in Table 2 and the coefficient of determination of Equation 9.

[0174] Mathematical Formula Number Independent Variable (X) Dependent Variable (Y) Regression Equation R 2 6MRGPRX2 mRNAHistamine(μg / mL)Y = 27.71 155.320.9630

[0175]

[0176] Next, normalized weights to be applied to the predicted values ​​of the first to third paths were calculated based on the effective coefficient of determination (R²) of each path. Specifically, the sum of the effective coefficient of determination of the first path (0.9893), the effective coefficient of determination of the second path (0.9815), and the effective coefficient of determination of the third path (0.9630) was calculated to be 2.9338.

[0177] Accordingly, as a result of normalizing the effective coefficient of determination of each path by dividing it by the above sum, the weights of the first path, the second path, and the third path were calculated to be 0.3372, 0.3345, and 0.3282, respectively.

[0178] Subsequently, the above normalization weights were applied to the histamine concentration prediction values ​​calculated in the first, second, and third pathways, respectively, and summed to calculate the ensemble-type histamine concentration prediction values. Specifically, a weight of 0.3372 was applied to the histamine concentration prediction value of the first pathway, a weight of 0.3345 to the histamine concentration prediction value of the second pathway, and a weight of 0.3282 to the histamine concentration prediction value of the third pathway.

[0179] The above normalized weights were applied to the histamine concentration prediction equations of each pathway to calculate the slopes and intercepts of the ensemble prediction equations. Specifically, the slopes of the first to third pathways were multiplied by their respective normalized weights and then summed, and the intercepts of the first to third pathways were also multiplied by their respective normalized weights and then summed.

[0180] As a result, the slope of the ensemble prediction equation was calculated to be 32.71, and the intercept of the ensemble prediction equation was calculated to be 146.48. Accordingly, the final ensemble histamine concentration prediction equation based on the relative expression level of MRGPRX2 mRNA was derived as follows.

[0181] [Mathematical Formula 14]

[0182] Y = 32.71X + 146.48

[0183] Here, Y is the histamine concentration, and X is the relative expression level of MRGPRX2 mRNA.

[0184] In addition, error propagation analysis was performed to compare the histamine concentration prediction errors for each pathway. The sample standard deviation in the histamine measurement range of 0 to 800 μg / mL was set to approximately 300 μg / mL, and the residual standard error was estimated based on the effective coefficient of determination for each pathway. As a result, the residual standard error for the first pathway was calculated to be 31.03 μg / mL, the residual standard error for the second pathway was 40.79 μg / mL, and the residual standard error for the third pathway was 57.71 μg / mL.

[0185] Furthermore, the predicted value of the above multipath is R 2 As a result of integrating using a weighting method, the effective coefficient of determination of the ensemble model was calculated to be 0.9927, confirming that the reliability of histamine concentration prediction can be improved by integrating multiple prediction paths.

[0186]

[0187] [Example 10] Cross-verification of predicted histamine concentrations using β-hexosaminidase release levels

[0188] To confirm whether the ensemble histamine prediction value calculated in Example 9 above corresponds to the functional response of mast cells, cross-confirmation can be performed using the β-hexosaminidase release level.

[0189] The β-hexosaminidase release level (%) is an indicator reflecting the level of degranulation of mast cells and can be used as an auxiliary indicator to confirm the degree of histamine-induced mast cell response.

[0190] Specifically, based on the regression equation between the histamine concentration and the β-hexosaminidase release level identified in Table 2 above, the β-hexosaminidase release level can be predicted from the ensemble histamine concentration prediction value calculated in Example 9. At this time, the β-hexosaminidase release level (β-hexosaminidase) calculated from the histamine concentration prediction value. from H) can be expressed by mathematical formula 11 of Table 2 above.

[0191] In addition, based on the regression equation between the MRGPRX2 mRNA expression level and the β-hexosaminidase release level identified in Table 2 above, the β-hexosaminidase release level can be directly predicted from the MRGPRX2 mRNA expression level. At this time, the β-hexosaminidase release level (β- from mRNA ) can be expressed by mathematical formula 8 of Table 2 above.

[0192] Subsequently, the biological consistency of the ensemble histamine concentration predictions can be determined by comparing the β-hexosaminidase release predictions calculated from the two aforementioned pathways. That is, the β calculated from the histamine concentration predictions from H and β directly calculated from MRGPRX2 mRNA expression levels from mRNA The more similar they are to each other, the more consistent the predicted histamine concentration values ​​can be considered to be with the degranulation reaction of mast cells.

[0193] For example, the difference between the two predicted β-hexosaminidase release values ​​above can be calculated using the following mathematical formula 15.

[0194] [Mathematical Formula 15]

[0195] Δβ = |β from H - β from mRNA |

[0196] Here, Δβ represents the difference between the predicted β-hexosaminidase release values ​​calculated from the two pathways. A smaller Δβ value indicates a higher degree of agreement between the predicted histamine concentration and the MRGPRX2 mRNA-based degranulation prediction.

[0197] Therefore, using the above Δβ, it is possible to supplementarily evaluate whether the predicted ensemble histamine concentration is biologically consistent with the degranulation reaction of mast cells.

[0198]

[0199] [Example 11] Application of MRGPRX2 mRNA-based histamine evaluation method to fermented food samples

[0200] In Examples 5 and 6 above, the MRGPRX2 mRNA expression level and mast cell degranulation level were confirmed following treatment with fermented food samples. In this example, to more specifically confirm the correlation between the histamine content in fermented food samples and mast cell response indicators, the histamine content, MRGPRX2 mRNA expression level, and β-hexosaminidase release level were analyzed for fermented soy sauce and fermented shrimp paste samples.

[0201] Traditional fermented soy sauce DS and FS, commercially available soy sauce JS, and fermented shrimp paste FSS were used as samples. Each sample was diluted to a salinity condition that does not affect the cells and then treated with HMC-1.2 human mast cells. The results of analyzing MRGPRX2 mRNA expression levels and β-hexosaminidase release levels after treating HMC-1.2 cells with the samples are shown in Figure 11.

[0202] First, as a result of analyzing the histamine content of each sample, DS, FS, and JS showed histamine content of 176.57±3.62 mg / L, 162.92±1.21 mg / L, and 165.48±2.41 mg / L, respectively. On the other hand, FSS showed a histamine content of 685.80±24.13 mg / L, confirming that it had a higher histamine content than the fermented soy sauce samples.

[0203]

[0204]

[0205] Next, after treating HMC-1.2 cells with the above sample, the MRGPRX2 mRNA expression level was analyzed. The DS, FS, and JS treatment groups showed MRGPRX2 mRNA expression levels similar to the control group, whereas the MRGPRX2 mRNA expression level in the FSS treatment group increased significantly (Fig. 11).

[0206] In addition, analysis of the β-hexosaminidase release levels following the sample treatment showed that no significant increase in β-hexosaminidase release levels was observed in the DS, FS, and JS treatment groups, whereas the β-hexosaminidase release level increased in the FSS treatment group (Fig. 11).

[0207] From the above results, it was confirmed that in fermented soy sauce samples with a histamine content of 200 mg / L or less, the increase in MRGPRX2 mRNA expression and β-hexosaminidase release levels was not significant, whereas in fermented shrimp paste samples with high histamine content, both MRGPRX2 mRNA expression and β-hexosaminidase release levels increased. Therefore, it was confirmed that the MRGPRX2 mRNA-based evaluation method of the present invention can be applied to evaluate the histamine content in actual fermented food samples and the resulting mast cell functional response.

[0208]

[0209] Foregoing, specific parts of the content of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

1. 1) Step of treating mast cells with the sample; 2) a step of measuring MRGPRX2 (MAS related GPR family member X2) related signals in mast cells treated with the above sample; and 3) a step of estimating the histamine concentration in the sample using the measured MRGPRX2-related signal; a method for evaluating safety related to biogenic amines in a sample.

2. The method of claim 1, wherein the method further comprises the step of evaluating the biogenic amine-related safety of the sample by comparing the estimated histamine concentration with a preset reference value.

3. The method of claim 1, wherein the MRGPRX2-related signal is one or more selected from the group consisting of MRGPRX2 mRNA expression level, MRGPRX2 protein level, and mast cell response indicators associated with MRGPRX2 activation.

4. The method according to paragraph 3, wherein the mast cell response indicator associated with MRGPRX2 activation is the TPSAB1 mRNA expression level or the β-hexosaminidase release level.

5. Method according to claim 1, wherein, when the MRGPRX2-related signal is the MRGPRX2 mRNA expression level, step 3) is to estimate the histamine concentration through a linear prediction equation represented by the following mathematical formula 16: [Mathematical Formula 16] Y = aX + b Here, Y is the histamine concentration (μg / mL), and X is the relative expression level of MRGPRX2 mRNA, The above a and b are coefficient pairs calculated together by regression analysis on a calibration dataset between MRGPRX2 mRNA relative expression levels and histamine concentrations, and a is 27 to 42, and b is 72 to 170.

6. A method according to claim 5, wherein a and b are each selected from pairs of coefficients consisting of 30.43 and 74.64, 27.71 and 168.3, 41.68 and 115.93, 28.72 and 155.32, or 32.71 and 146.

48.

7. Method of claim 1, wherein, when the MRGPRX2-related signal is at the MRGPRX2 protein level, step 3) is to estimate the histamine concentration through a linear prediction equation represented by the following mathematical formula 17: [Mathematical Formula 17] Y = cX + d Here, Y is the histamine concentration (μg / mL), X is the MRGPRX2 protein level (ng / mL), and The above c and d are pairs of coefficients calculated together by regression analysis on a calibration dataset between MRGPRX2 protein levels and histamine concentrations, and c is 46 to 48, and d is 132 to 136.

8. A method according to claim 7, wherein c and d are coefficient pairs of 46.79 and 134.2, respectively.

9. Method according to claim 1, wherein, when the MRGPRX2-related signal is the TPSAB1 mRNA expression level, step 3) is to estimate the histamine concentration through a linear prediction equation represented by the following mathematical formula 18: [Mathematical Formula 18] Y = eX + f Here, Y is the histamine concentration (μg / mL), and X is the relative expression level of TPSAB1 mRNA, The above e and f are pairs of coefficients calculated together by regression analysis on a calibration dataset between TPSAB1 mRNA relative expression levels and histamine concentrations, and The above e is 24 to 26, and f is 154 to 158.

10. A method according to claim 9, wherein e and f are coefficient pairs of 25.04 and 156.4, respectively.

11. The method according to claim 1, wherein the sample is a food, household product, pharmaceutical, or composition containing or potentially containing a biogenic amine.

12. The method according to claim 1, wherein the mast cells are human-derived mast cells. 13.1) A processing unit for bringing the sample into contact with mast cells; 2) A measurement unit for measuring MRGPRX2 (MAS related GPR family member X2) related signals in mast cells treated with the above sample; and 3) A calculation unit that calculates the histamine concentration in the sample using the measured MRGPRX2-related signal; comprising an apparatus for evaluating safety related to biogenic amines in a sample.

14. The apparatus of claim 11, wherein the apparatus further comprises an evaluation unit that evaluates the biogenic amine-related safety of the sample by comparing the calculated histamine concentration with a preset reference value.